Xellia Pharms Aps Drug Patent Portfolio

Xellia Pharms Aps owns 3 orange book drugs protected by 8 US patents Given below is the list of Xellia Pharms Aps's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11759497 Daptomycin formulations 28 Aug, 2038
Active
US12053502 Daptomycin formulations 28 Aug, 2038
Active
US10039804 Glycopeptide compositions 06 Nov, 2035
Active
US10188697 Glycopeptide compositions 06 Nov, 2035
Active
US10849956 Glycopeptide compositions 06 Nov, 2035
Active
US11000567 Glycopeptide compositions 06 Nov, 2035
Active
US11517609 Glycopeptide compositions 06 Nov, 2035
Active
US11628200 Glycopeptide compositions 06 Nov, 2035
Active


Given below is the list of recent legal activities going on the following drug patents of Xellia Pharms Aps.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 4th Year, Large Entity 15 May, 2024 US10849956
Payment of Maintenance Fee, 4th Year, Large Entity 15 May, 2024 US10849956
Email Notification 20 Sep, 2023 US11759497
Recordation of Patent eGrant 19 Sep, 2023 US11759497
Patent eGrant Notification 19 Sep, 2023 US11759497
Patent Issue Date Used in PTA Calculation 19 Sep, 2023 US11759497
Recordation of Patent Grant Mailed 19 Sep, 2023 US11759497
Mail Patent eGrant Notification 19 Sep, 2023 US11759497
Email Notification 01 Sep, 2023 US11759497
Issue Notification Mailed 30 Aug, 2023 US11759497
Dispatch to FDC 09 Aug, 2023 US11759497
Application Is Considered Ready for Issue 09 Aug, 2023 US11759497
Issue Fee Payment Verified 08 Aug, 2023 US11759497
Issue Fee Payment Received 08 Aug, 2023 US11759497
Email Notification 24 May, 2023 US11759497


Xellia Pharms Aps Drug Patents' Oppositions Filed in EPO

Xellia Pharms Aps drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Oct 01, 2020, by Df-Mp Dörries Frank-Molnia & Pohlman Patentanwälte Rechtsanwälte Parg Mbb. This opposition was filed on patent number EP15791287A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP15791287A Oct, 2020 df-mp Dörries Frank-Molnia & Pohlman Patentanwälte Rechtsanwälte ParG mbB Revoked


Xellia Pharms Aps's Family Patents

Xellia Pharms Aps drugs have patent protection in a total of 27 countries. It's US patent count contributes only to 20.4% of its total global patent coverage. 2 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Xellia Pharms Aps Drug List

Given below is the complete list of Xellia Pharms Aps's drugs and the patents protecting them.


1. Daptomycin

Daptomycin is protected by 2 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11759497 Daptomycin formulations 28 Aug, 2038
(13 years from now)
Active
US12053502 Daptomycin formulations 28 Aug, 2038
(13 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Daptomycin's drug page


2. Vancomycin

Vancomycin is protected by 5 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10039804 Glycopeptide compositions 06 Nov, 2035
(11 years from now)
Active
US10188697 Glycopeptide compositions 06 Nov, 2035
(11 years from now)
Active
US10849956 Glycopeptide compositions 06 Nov, 2035
(11 years from now)
Active
US11000567 Glycopeptide compositions 06 Nov, 2035
(11 years from now)
Active
US11517609 Glycopeptide compositions 06 Nov, 2035
(11 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vancomycin's drug page


3. Vancomycin Hydrochloride

Vancomycin Hydrochloride is protected by 5 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10039804 Glycopeptide compositions 06 Nov, 2035
(11 years from now)
Active
US10188697 Glycopeptide compositions 06 Nov, 2035
(11 years from now)
Active
US10849956 Glycopeptide compositions 06 Nov, 2035
(11 years from now)
Active
US11517609 Glycopeptide compositions 06 Nov, 2035
(11 years from now)
Active
US11628200 Glycopeptide compositions 06 Nov, 2035
(11 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vancomycin Hydrochloride's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List